348 related articles for article (PubMed ID: 17089122)
1. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):480-6. PubMed ID: 17089122
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.
Chung HH; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB
Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1081-8. PubMed ID: 18180917
[TBL] [Abstract][Full Text] [Related]
3. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
Sironi S; Picchio M; Landoni C; Galimberti S; Signorelli M; Bettinardi V; Perego P; Mangioni C; Messa C; Fazio F
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):472-9. PubMed ID: 17106701
[TBL] [Abstract][Full Text] [Related]
4. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?
Zoller M; Kohlfuerst S; Igerc I; Kresnik E; Gallowitsch HJ; Gomez I; Lind P
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):487-95. PubMed ID: 17103166
[TBL] [Abstract][Full Text] [Related]
5. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
6. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
8. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
[TBL] [Abstract][Full Text] [Related]
9. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
10. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.
Kitajima K; Murakami K; Yamasaki E; Domeki Y; Kaji Y; Fukasawa I; Inaba N; Suganuma N; Sugimura K
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1439-48. PubMed ID: 18418592
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
13. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings.
Sironi S; Messa C; Mangili G; Zangheri B; Aletti G; Garavaglia E; Vigano R; Picchio M; Taccagni G; Maschio AD; Fazio F
Radiology; 2004 Nov; 233(2):433-40. PubMed ID: 15516617
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
16. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
17. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment.
Picchio M; Sironi S; Messa C; Mangili G; Landoni C; Gianolli L; Zangheri B; Viganò R; Aletti G; De Marzi P; De Cobelli F; Del Maschio A; Ferrari A; Fazio F
Q J Nucl Med; 2003 Jun; 47(2):77-84. PubMed ID: 12865867
[TBL] [Abstract][Full Text] [Related]
20. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
